

PATENT Attorney Docket No. 056291-5296

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)		
David Michael ANDREWS, et al.	Confirmation No.: 3394		
Application No.: 10/586,954) Group Art Unit: 1614		
Filed: July 25, 2006	Examiner: Unassigned		
For: IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION) Date: April 20, 2007)		

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

ATTORNEY DOCKET NO.: 056291-5296

Application No.: 10/586,954

Page 2

This submission does not represent that a search has been made or that no better art exists and

does not constitute an admission that each or all of the listed documents are material or constitute

"prior art." Applicants reserve the right to take appropriate action to establish the patentability of the

disclosed invention over the listed documents, should one or more of the documents be applied against

the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized

by this paper to charge any additional fees during the entire pendency of this application including fees

due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time

fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §

1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockiu

Date:

April 20, 2007

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5915 Fax No.: (202) 739-3001

Attorney Docket No. Application No.: INFORMATION DISCLOSURE CITATION 056291-5296-US 10/586,954 (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 **U.S. PATENT DOCUMENTS** Initial Document No. Date Name Class Sub-Class Filing Date **A**1 US 4,983,608 January 8, 1991 Effland et al. A2 US 5,516,775 May 14, 1996 Zimmerman et al. **A3** US 5,521,184 May 28, 1996 Zimmermann A4 US 5,610,303 March 11, 1997 Kimura et al. US 5,739,143 April 14, 1998 Adams et al. A5 **A6** US 5,859,041 January 12, 1999 Liverton et al. December 28, 2004 A7 US 6,835,726 Cushing et al. A8 US 20030144303 July 31, 2003 Hawley et al. Α9 US 20060079543 April 13, 2006 Sum et al. A10 US 20030191307 October 9, 2003 Blumenkopf et al. FOREIGN PATENT DOCUMENTS Document No. Country Class Sub-Class Date Translation CA 2231765 **B**1 September 13, 1998 Canada B2 EP 0135472 January 18, 1989 **EPO** US 4,659,363 June 22, 1994 **B3** EP 0363002 **EPO B4** EP 0379806 April 10, 1996 **EPO** EP 0945443 **B5** August 13, 2003 **EPO B6** EP 1056742 July 23, 2003 **EPO** HU 220630 March 28, 2002 B7 Hungary Claims B8 WO 91/18887 December 12, 1991 **WIPO** B9 WO 92/20642 November 26, 1992 **WIPO** B10 WO 95/09847 April 13, 1995 **WIPO** B11 WO 95/09851 April 13, 1995 **WIPO** WO 95/09852 **B12** April 13, 1995 **WIPO** B13 WO 95/09853 April 13, 1995 WIPO B14 June 15, 1995 WO 95/15952 **WIPO** B15 WO 96/05177 February 22, 1996 **WIPO** WO 96/28427 B16 September 19, 1996 WIPO **B17** WO 96/40143 December 19, 1996 WIPO B18 WO 97/19065 May 29, 1997 WIPO B19 WO 97/35856 October 2, 1997 WIPO **B20** WO 97/40017 October 30, 1997 **WIPO** B21 WO 97/44326 November 27, 1997 WIPO B22 WO 9747618 December 18, 1997 WIPO **B23** WO 98/11095 March 19, 1998 **WIPO B24** WO 98/16230 April 23, 1998 WIPO B25 May 7, 1998 WO 98/18782 WIPO WIPO **B26** WO 98/25619 June 18, 1998 B27 WO 98/33798 August 6, 1998 **WIPO** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No. Application No.: 056291-5296-US 10/586,954 INFORMATION DISCLOSURE CHATION (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 **PTO Form 1449** Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 **U.S. PATENT DOCUMENTS** Initial Document No. **Date** Name Class Sub-Class Filing Date FOREIGN PATENT DOCUMENTS Document No. Date Country Sub-Class Translation Class WIPO WO 98/41512 September 24, 1998 **B28** WIPO **B29** WO 98/54093 December 3, 1998 WIPO B30 WO 98/56788 December 17, 1998 WO 99/01136 Jan 14, 1999 WIPO B31 WO 99/18096 April 22, 1999 WIPO **B32** WO 99/18942 April 22, 1999 WIPO B33 WO 99/31073 B34 June 24, 1999 WIPO US 6,432,963 B35 WO 99/32121 July 1, 1999 **WIPO B36** WO 99/41253 August 19, 1999 **WIPO** October 7, 1999 **B37** WO 99/50250 WIPO **B38** WO 99/50251 October 7, 1999 WIPO WO 00/12485 B39 March 9, 2000 **WIPO B40** WO 00/12486 March 9, 2000 WIPO B41 WO 00/17202 March 30, 2000 WIPO B42 WO 00/17203 March 30, 2000 **WIPO** WO 00/21926 B43 April 20, 2000 **WIPO** WO 00/25780 May 11, 2000 B44 WIPO B45 WO 00/26209 May 11, 2000 **WIPO** B46 WO 00/39101 July 6, 2000 **WIPO B47** WO 00/44750 August 3, 2000 WIPO **B48** August 24, 2000 WO 00/49018 WIPO September 14, 2000 **B49** WO 00/53595 **WIPO B50** WO 00/55161 September 21, 2000 **WIPO** B51 WO 00/59892 October 12, 2000 WIPO B52 WO 00/78731 WIPO December 28, 2000 **B53** WO 01/14375 March 1, 2001 **WIPO B54** WO 01/29009 April 26, 2001 **WIPO** B55 WO 01/30778 May 3, 2001 **WIPO B56** WO 01/37835 May 31, 2001 WIPO B57 WO 01/47897 July 5, 2001 WIPO B58 WO 01/47921 July 5, 2001 WIPO **B59** WO 01/60816 August 23, 2001 WIPO B60 WO 01/64653 September 7, 2001 WIPO B61 WO 01/64654 September 7, 2001 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Application No.: Attorney Docket No. 10/586,954 INFORMATION DISCLOSURE CITATION 056291-5296-US (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 200 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 TENT DOCUMENTS Initial Document No. Name Class Sub-Class Filing Date FOREIGN PATENT DOCUMENTS Document No. Date Class Sub-Class Country Translation B62 WO 01/64655 September 7, 2001 WIPO September 7, 2001 WO 01/64656 B63 WIPO B64 WO 01/72717 October 4, 2001 WIPO WO 02/04429 B65 January 17, 2002 WIPO WO 02/65979 August 29, 2002 **B66** WIPO **B67** WO 02/66481 August 29, 2002 WIPO **B68** WO 02/92573 November 21, 2002 **WIPO** B69 WO 02/96887 December 5, 2002 **WIPO** B70 WO 02/96888 December 5, 2002 **WIPO** US 20040224966 B71 WO 03/007955 January 30, 2003 WIPO B72 WO 03/029249 April 10, 2003 WIPO B73 WO 03/031446 April 17, 2003 WIPO B74 WO 03/076433 September 18, 2003 WIPO B75 WO 03/076434 September 18, 2003 WIPO B76 WO 03/076435 September 18, 2003 WIPO **B77** WO 03/076436 September 18, 2003 **WIPO B78** WO 04/005283 January 15, 2004 WIPO B79 WO 04/043467 May 27, 2004 **WIPO** B80 WO 04/043953 May 27, 2004 WIPO B81 WO 04/087698 October 14, 2004 **WIPO** B82 WO 04/087699 October 14, 2004 **WIPO** B83 WO 04/101549 November 25, 2004 WIPO B84 WO 04/101564 November 25, 2004 WIPO B85 WO 05/012298 February 10, 2005 **WIPO** WO 05/037800 B86 April 28, 2005 **WIPO B87** WO 05/075468 August 18, 2005 **WIPO** B88 WO 05/113550 December 1, 2005 WIPO Abstract B89 WO 05/116025 December 8, 2005 **WIPO B90** WO 06/034872 April 6, 2006 **WIPO B91** WO 06/050076 May 11, 2006 **WIPO** B92 WO 06/064251 June 22, 2006 WIPO B93 WO 06/075152 July 20, 2006 WIPO B94 WO 06/095159 September 14, 2006 WIPO Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Attomas Daglas Na	Т	Λ	mlication No.			
INFORMATION DISCLOSURE CITATION			Attorney Docket No. 056291-5296-US		Application No.: 10/586,954					
INFOR	(U	se several sheets if nece	255 Q)	Applicants: ANDREWS et al.						
PTO Form 1449 APR 2 0 2007 April 20, 2007			Filing Date: July 25, 2006		Group Art Unit: 1614					
U.S. PATENT DOCUMENTS										
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date			
FOREIGN PATENT DOCUMENTS										
		Document No.	Date	Country	Class	Sub-Class	Translation			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Blain, S. et al. "Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27 ^{Kip1} with cyclin A-Cdk2 and										
	C1	cyclin D2-Cdk4" The Journal of Biological Chemistry, 1997, Vol 272, No.41, pp 25863-25872.								
	C2	Boschelli, D. et al. "Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors" J.								
	C3	Med. Chem., 1998, Vol 41, pp 4365-4377. Deady L. et al. "Reactions of some quinazoline compounds with ethoxymethylenemalonic acid derivatives" J. Heterocyclic Chem., 1989, Vol 26, pp 161-168.								
	C4	El-Kerdawy, M. et al. "2,4-Bis(substituted)-5-nitropyrimidines of expected diuretic action" Egypt. J. Chem., 1986, 29, Vol 2, No. 2, pp 247-251.								
	C5	Fiziol Akt Veshchestva, 1975, 7, pp 68-72.								
	C6	Ghosh, D. et al. "2,4-Bis(arylamino)-5-methylpyrimidines as antimicrobial agents" J. Med. Chem., 1967, Vol 10, pp 974-975.								
		Ghosh, D., "2,4-Bis(arylamino)-6-methyl pyrimidines as antimicrobial agents" Chemical Abstracts, 1981, Vol 95, No.11, Columbus, Ohio, US; Abstract No. 97712f; pp 648; XP002109184 abstract & J. Indian Chem. Soc., 1981, Vol 58, No.5, pp 512-513, India.								
	C8	Schmidt, H. et al. "A convenient synthesis of 2-substituted 4-amino-5-pyrimidinecarbonitriles" J. Heterocyclic Chem., 1987, Vol 24, pp 1305-1307.								
	C9									
		d594-601.								
	C11	Zimmermann, J. et al. "Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)" Arch. Pharm. Pharm. Med. Chem. 1996, 329 (7), pp 371-376.								
					_					
					_					
	ļ						<u></u>			
						•				
Examiner			Date Co	onsidered	-					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in										